Global Gastrointestinal Cancer Drug Market By Type (By Therapy, Immunotherapy, Chemotherapy, Targeted Therapy, Radiation Therapy, Hormone Therapy, Adjuvant Chemotherapy, By Route of Administration, Oral, and Injectable Therapy), By Application (Radiology, and Oncology), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029
- Published date: Jul 2022
- Report ID: 49229
- Number of Pages: 370
- Format:
- keyboard_arrow_up
- 1. Gastrointestinal Cancer Drug Market Introduction
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 2. Executive Summary
- 2.1. Key Findings by Major Segments
- 2.2. Top strategies by Major Players
- 3. Global Gastrointestinal Cancer Drug Market Overview
- 3.1. Gastrointestinal Cancer Drug Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Opportunities
- 3.1.3. Restraints
- 3.1.4. Challenges
- 3.2. PESTLE Analysis
- 3.3. Opportunity Map Analysis
- 3.4. PORTER'S Five Forces Analysis
- 3.5. Market Competition Scenario Analysis
- 3.6. Product Life Cycle Analysis
- 3.7. Opportunity Orbits
- 3.8. Production Analysis by Region/Company
- 3.9. Industry chain Analysis
- 3.10. Marketing Strategy
- 3.1. Gastrointestinal Cancer Drug Market Dynamics
- 4. Global Gastrointestinal Cancer Drug Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
- 4.1. Global Gastrointestinal Cancer Drug Market Analysis by Type: Introduction
- 4.2. Market Size and Forecast by Region
- 4.3. By Therapy
- 4.4. Immunotherapy
- 4.5. Chemotherapy
- 4.6. Targeted Therapy
- 4.7. Radiation Therapy
- 4.8. Hormone Therapy
- 4.9. Adjuvant Chemotherapy
- 4.10. By Route of Administration
- 4.11. Oral
- 4.12. Injectable Therapy
- 5. Global Gastrointestinal Cancer Drug Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
- 5.1. Global Gastrointestinal Cancer Drug Market Analysis by Application: Introduction
- 5.2. Market Size and Forecast by Region
- 5.3. Radiology
- 5.4. Oncology
- 6. Global Gastrointestinal Cancer Drug Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
- 6.1. North America
- 6.1.1. North America Gastrointestinal Cancer Drug Market: Regional Trend Analysis
- 6.1.1.1. US
- 6.1.1.2. Canada
- 6.1.1.3. Mexico
- 6.1.1. North America Gastrointestinal Cancer Drug Market: Regional Trend Analysis
- 6.2.1. Europe
- 6.2.1. Europe Gastrointestinal Cancer Drug Market: Regional Trend Analysis
- 6.2.1.1. Germany
- 6.2.1.2. France
- 6.2.1.3. UK
- 6.2.1.4. Russia
- 6.2.1.5. Italy
- 6.2.1.6. Spain
- 6.2.1.7. Rest of Europe
- 6.2.1. Europe Gastrointestinal Cancer Drug Market: Regional Trend Analysis
- 6.3. Asia-Pacific
- 6.3.1. Asia-Pacific Gastrointestinal Cancer Drug Market: Regional Trend Analysis
- 6.3.1.1. China
- 6.3.1.2. Japan
- 6.3.1.3. Korea
- 6.3.1.4. India
- 6.3.1.5. Rest of Asia-Pacific
- 6.3.1. Asia-Pacific Gastrointestinal Cancer Drug Market: Regional Trend Analysis
- 6.4. Latin America
- 6.4.1. Latin America Gastrointestinal Cancer Drug Market: Regional Trend Analysis
- 6.4.1.1. Brazil
- 6.4.1.2. Argentina
- 6.4.1.3. Rest of Latin America
- 6.4.1. Latin America Gastrointestinal Cancer Drug Market: Regional Trend Analysis
- 6.5. Middle East and Africa
- 6.5.1. Middle East and Africa Gastrointestinal Cancer Drug Market: Regional Trend Analysis
- 6.5.1.1. GCC
- 6.5.1.2. South Africa
- 6.5.1.3. Israel
- 6.5.1.4. Rest of MEA
- 6.5.1. Middle East and Africa Gastrointestinal Cancer Drug Market: Regional Trend Analysis
- 6.1. North America
- 7. Global Gastrointestinal Cancer Drug Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 7.1. Market Share Analysis
- 7.2. Company Profiles
- 7.3. Celgene Corporation
- 7.3.1. Company Overview
- 7.3.2. Financial Highlights
- 7.3.3. Product Portfolio
- 7.3.4. SWOT Analysis
- 7.3.5. Key Strategies and Developments
- 7.4. F. Hoffmann-La Roche
- 7.4.1. Company Overview
- 7.4.2. Financial Highlights
- 7.4.3. Product Portfolio
- 7.4.4. SWOT Analysis
- 7.4.5. Key Strategies and Developments
- 7.5. Eli Lilly and Company
- 7.5.1. Company Overview
- 7.5.2. Financial Highlights
- 7.5.3. Product Portfolio
- 7.5.4. SWOT Analysis
- 7.5.5. Key Strategies and Developments
- 7.6. GlaxoSmithKline
- 7.6.1. Company Overview
- 7.6.2. Financial Highlights
- 7.6.3. Product Portfolio
- 7.6.4. SWOT Analysis
- 7.6.5. Key Strategies and Developments
- 7.7. Pfizer
- 7.7.1. Company Overview
- 7.7.2. Financial Highlights
- 7.7.3. Product Portfolio
- 7.7.4. SWOT Analysis
- 7.7.5. Key Strategies and Developments
- 7.8. Sanofi
- 7.8.1. Company Overview
- 7.8.2. Financial Highlights
- 7.8.3. Product Portfolio
- 7.8.4. SWOT Analysis
- 7.8.5. Key Strategies and Developments
- 7.9. Novartis AG
- 7.9.1. Company Overview
- 7.9.2. Financial Highlights
- 7.9.3. Product Portfolio
- 7.9.4. SWOT Analysis
- 7.9.5. Key Strategies and Developments
- 7.10. Bristol-Myers Squibb Company
- 7.10.1. Company Overview
- 7.10.2. Financial Highlights
- 7.10.3. Product Portfolio
- 7.10.4. SWOT Analysis
- 7.10.5. Key Strategies and Developments
- 7.11. Amgen Limited & Amgen Ireland Limited
- 7.11.1. Company Overview
- 7.11.2. Financial Highlights
- 7.11.3. Product Portfolio
- 7.11.4. SWOT Analysis
- 7.11.5. Key Strategies and Developments
- 7.12. Johnson & Johnson Private Limited
- 7.12.1. Company Overview
- 7.12.2. Financial Highlights
- 7.12.3. Product Portfolio
- 7.12.4. SWOT Analysis
- 7.12.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- 1. Gastrointestinal Cancer Drug Market Introduction
- Celgene Corporation
- F. Hoffmann-La Roche
- Eli Lilly and Company
- GlaxoSmithKline
- Pfizer Inc Company Profile
- Sanofi Company Profile
- Novartis AG Company Profile
- Bristol-Myers Squibb Company
- Amgen Limited & Amgen Ireland Limited
- Johnson & Johnson Private Limited
- settingsSettings
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
Single User
$5,999
$2,999
USD / per unit
save 50% |
Multi User
$7,999
$3,499
USD / per unit
save 55% |
Corporate User
$12,999
$4,499
USD / per unit
save 65% | |
---|---|---|---|
e-Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 2,999) | Buy Now ($ 3,499) | Buy Now ($ 4,499) |